Afro-Egypt J Infect Endem
Dis 2015 March ; 5(1):40-50
Diagnostic
and Prognostic Validity of Serum Golgi Protein 73 in Egyptian Patients with
Hepatocelluar Carcinoma
El Khashab MN, Khorshed SE, Toam MM,Abdelmoety H , Awad SM
Tropical Medicine Department, Faculty of Medicine, Zagazig University, Egypt
sohaesmat@hotmail.com
ABSTRACT
Background and study aim :
Hepato-cellular carcinoma (HCC) is common all over the world. Most HCC are
diagnosed at an advanced stage . We aimed to detect
the serum Golgi protein (GP 73) in patients
with cirrhosis and HCC as non-invasive marker
for diagnosis and prognosis of HCC.
Patients and Methods:
This study was conducted on 81 subjects: They
were divided into 3 groups : 27 patients with HCC, 27
patients with liver cirrhosis and 27 healthy
control subjects. Serum alphaphetoprotein
(AFP) and GP 73 were estimated by ELISA.
In addition, GP 73 was remasured after therapy in patients with HCC who were
treated by percutaneous ethanol injection.
Results:
GP 73 was
elevated in patients with HCC and liver cirrhosis ; serum level was high in HCC
patients (p<0.01) when compared with the other studied groups. GP 73 had
sensitivity of 81.4% and specificity of 100% at a cut-off value 4.12 ng/ml with
area under the receiver operator characteristics (AUC) of 0.964 when compared
with AFP that showed a sensitivity 77.7% , specificity 85.1% at a cut-off value
>200 and (AUC) 0.774. when AFP was combined with GP73 for the diagnosis of HCC,
sensitivity and specificity were increased to 87.6% and 100% respectively. At
six week after ethanol injection, a significant decrease in GP73 occurred.
Conclusion:
Serum GP 73 can be used as a useful biomarker to confirm the diagnosis of HCC especially if
combined with AFP and GP73 had promising prognostic value as it decreased after
the treatment of HCC and is correlated to tumor size